Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

Background: Previous meta-analyses of atypical antipsychotics for depression were limited by few trials with direct comparisons between two treatments. We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant depression (TRD). Methods: Systematic searches resulted in 18 RCTs (total n = 4422) of seven different types and different dosages of atypical antipsychotics and a placebo that were included in the review. Results: All standard-dose atypical antipsychotics were significantly more efficacious than placebo in the efficacy (standardized mean differences [SMDs] ranged from -0.27 to -0.43). There were no significant differences between these drugs. Low-dose atypical antipsychotics were not significantly more efficacious than the placebo. In terms of tolerability, all standard-dose atypical antipsychotics, apart from risperidone, had significantly more side-effect discontinuations than placebo (odds ratios [ORs] ranged from 2.72 to 6.40). In terms of acceptability, only quetiapine (mean 250–350mg daily) had significantly more all-cause discontinuation than placebo (OR = 1.89). In terms of quality of life/functioning, standard-dose risperidone and standard-dose aripiprazole were more beneficial than placebo (SMD = -0.38; SMD = -0.26, respectively), and standard-dose risperidone was superior to quetiapine (mean 250–350mg daily). Conclusions: All standard-dose atypical antipsychotics for the adjunctive treatment of TRD are efficacious in reducing depressive symptoms. Risperidone and aripiprazole also showed benefits in improving the quality of life of patients. Atypical antipsychotics should be prescribed with caution due to abundant evidence of side effects.

[1]  Y. Fang,et al.  Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. , 2015, The Journal of clinical psychiatry.

[2]  G. Papakostas,et al.  The nature of placebo response in clinical studies of major depressive disorder. , 2015, The Journal of clinical psychiatry.

[3]  P. Xie,et al.  Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis , 2014, Systematic Reviews.

[4]  S. Kanba,et al.  Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). , 2013, Journal of affective disorders.

[5]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[6]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[7]  E. Linardatos,et al.  Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes , 2013, PLoS medicine.

[8]  G. Papakostas,et al.  Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. , 2012, The Journal of clinical psychiatry.

[9]  Feng Liu,et al.  Abnormal neural activity of brain regions in treatment-resistant and treatment-sensitive major depressive disorder: a resting-state fMRI study. , 2012, Journal of psychiatric research.

[10]  Feng Liu,et al.  Altered white matter integrity in young adults with first-episode, treatment-naive, and treatment-responsive depression , 2012, Neuroscience Letters.

[11]  M. Pencina,et al.  A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study) , 2012, Psychotherapy and Psychosomatics.

[12]  Andrea Cipriani,et al.  Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis , 2011, The Lancet.

[13]  Eduard Vieta,et al.  Therapeutic options in treatment-resistant depression , 2011, Annals of medicine.

[14]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[15]  R. Stafford,et al.  Increasing off‐label use of antipsychotic medications in the United States, 1995–2008 , 2011, Pharmacoepidemiology and drug safety.

[16]  S. Leucht,et al.  Second-generation antipsychotics for major depressive disorder and dysthymia. , 2010, The Cochrane database of systematic reviews.

[17]  P. Hicks,et al.  How best to manage treatment-resistant depression? , 2010, The Journal of family practice.

[18]  H. Eriksson,et al.  Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. , 2010, The international journal of neuropsychopharmacology.

[19]  R. Shelton,et al.  Therapeutic Options for Treatment-Resistant Depression , 2010, CNS drugs.

[20]  S. Patten,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. , 2009, Journal of affective disorders.

[21]  J. Nelson,et al.  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. , 2009, The American journal of psychiatry.

[22]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[23]  E. Constant,et al.  Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. , 2009, The Journal of clinical psychiatry.

[24]  M. Fava,et al.  Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants , 2009, CNS Spectrums.

[25]  F. Fregni,et al.  Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis , 2009, PloS one.

[26]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[27]  Rusheng Zhang,et al.  Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. , 2008, The Journal of clinical psychiatry.

[28]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[29]  J. Grimshaw,et al.  Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials , 2008, Canadian Medical Association Journal.

[30]  M. Fava,et al.  The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.

[31]  W. Gaebel,et al.  Side effects of atypical antipsychotics: a brief overview , 2008, World psychiatry : official journal of the World Psychiatric Association.

[32]  C. Kosik‐Gonzalez,et al.  Risperidone for Treatment-Refractory Major Depressive Disorder , 2007, Annals of Internal Medicine.

[33]  I. Kirsch,et al.  Clinical trials and the response rate illusion. , 2007, Contemporary clinical trials.

[34]  R. Berman,et al.  The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.

[35]  R. Shelton,et al.  Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. , 2007, The Journal of clinical psychiatry.

[36]  M. Thase,et al.  A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. , 2007, The Journal of clinical psychiatry.

[37]  Gustavo Turecki,et al.  Definition, Assessment, and Staging of Treatment—Resistant Refractory Major Depression: A Review of Current Concepts and Methods , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[38]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[39]  R. Berard,et al.  An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. , 2006, Journal of child and adolescent psychopharmacology.

[40]  John W Seaman,et al.  Multiple imputation techniques in small sample clinical trials , 2006, Statistics in medicine.

[41]  R. Shelton,et al.  Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. , 2005, The Journal of clinical psychiatry.

[42]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[43]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[44]  A. Rush,et al.  The impact of treatment-resistant depression on health care utilization and costs. , 2002, The Journal of clinical psychiatry.

[45]  David Taylor.  Low dose typical antipsychotics – a brief evaluation , 2000 .

[46]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[47]  D. Sheehan,et al.  The measurement of disability , 1996, International clinical psychopharmacology.

[48]  D. Sheehan,et al.  The measurement of disability. , 1996 .

[49]  T. Silverstone,et al.  The effects of D‐ and L‐fenfluramine (and their interactions with D‐amphetamine) on psychomotor function and mood , 1996, International clinical psychopharmacology.

[50]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[51]  D J Kupfer,et al.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. , 1991, Archives of general psychiatry.

[52]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.

[53]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[54]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[55]  Michael Frankfurter,et al.  Applied Therapeutics The Clinical Use Of Drugs , 2016 .

[56]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[57]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[58]  C. Nemeroff,et al.  A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. , 2009, Journal of psychiatric research.

[59]  J. Ballenger.  Augmentation of Antidepressants With Atypical Antipsychotic Medications for Treatment-Resistant Major Depressive Disorder: A Meta-Analysis , 2009 .

[60]  A. McIntyre,et al.  Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo‐controlled pilot study , 2007, Depression and anxiety.

[61]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[62]  M. Case,et al.  A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression , 2006, Depression and anxiety.

[63]  A. Hasanzadeh,et al.  COMPARISON OF EFFICACY OF FLUOXETINE WITH NORTRIPTYLINE IN TREATMENT OF MAJOR DEPRESSION IN CHILDREN AND ADOLESCENTS: A DOUBLE-BLIND STUDY , 2006 .

[64]  P. Blier,et al.  Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. , 2005, The Journal of clinical psychiatry.

[65]  Maurizio Fava,et al.  Quality of life assessments in major depressive disorder: a review of the literature. , 2004, General hospital psychiatry.

[66]  Wei Zhang,et al.  A novel augmentation strategy for treating resistant major depression. , 2001, The American journal of psychiatry.

[67]  J. Endicott,et al.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. , 1993, Psychopharmacology bulletin.

[68]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .